Joseph Balthasar, Abceutics founder
April 8, 2024 07:32 AM EDTUpdated 01:42 PM
Startups
Deals

Mer­ck signs small ac­qui­si­tion to make AD­Cs safer

Kyle LaHucik

Senior Reporter

An­ti­body-drug con­ju­gates have caught the bio­phar­ma world by storm, and Mer­ck has been an ac­tive deal­mak­er in the space via multi­bil­lion-dol­lar pacts

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times